An analysis of the major clinical trials dealing with the utilization of angiotensin receptor blockers (ARBs) suggests that the effect of ACE and ARBs inhibitors in patients infected by COVID-19 is strongly dependent on the severity and stage of the disease, on the time at which COVID-19 is diagnosed, on the dosage administered daily, and on the duration of the treatment [101]. Here, ACE is linked to COVID-19.